Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2009 Aug 11;8(8):2204–2210. doi: 10.1158/1535-7163.MCT-09-0160

Figure 1. NVP-BEZ235 treatment inhibits glioma proliferation and attenuates PI3K/mTOR signaling pathway.

Figure 1

(A) Glioma cells in 96-well plates were treated with increasing concentrations of NVP-BEZ235 for 72 h and subjected to an SRB assay, as described in Materials and Methods. Plot depicts the percentage growth of NVP-BEZ235-treated cells compared with the growth of the vehicle-treated control cells. Each culture was performed in triplicate. The results shown are the arithmetic mean ± the standard deviation from a single experiment. Similar results were obtained from three independent experiments. U251 and U87 cells are used as PTEN negative cells and LN18 and LN229 as PTEN positive cells. (B) To evaluate the target inactivation by NVP-BEZ235 in a time-dependent manner, glioma cells were treated with a fixed concentration of NVP-BEZ235 72 h. At each indicated time point, cell extracts were subjected to immunoblotting analysis.